Date(s) - Thursday, May 2, 2013
5:30 pm - 8:00 pm
- Date: May 2, 2013
- 5:30pm Registration
- 5:30-6:00pm Pizza and Social
- 6:00-8:00pm Gilead Presentation, Panel Discussion, and Q&A
- Location: Room 114 Alway Building, Stanford School of Medicine
- Dr. Guoliang Yu, Executive Chairman of Crownbio
- Dr. Wei Zhou, CEO at Centrillion Biosciences, Inc
- Dr. Sofie Qiao, Executive Director at Russell Reynolds Associates
- Dr. Hengwei Chang, CEO at CS Bio.
- Dr. Jimmy Z. Zhang, Managing Director, MSD Early Investment, Greater China Merck & Co., Inc
Parking: There is a parking place (Parking Struct 1) across the Campus Drive. Free after 4pm.
Bio of Dr. Guo-Liang Yu
Biotechnologist and entrepreneur Dr. Guo-Liang Yu has more than 12 years of experience in genomics and 24 years of experience in life sciences research. Before cofounding Epitomics, Dr. Yu was Senior Vice-President of Research and Development at Mendel Biotechnology Inc. While there, Dr. Yu established a robust functional genomics program, exceeded all six milestones for the Research Agreement with Monsanto and Savia, all while managing more than 60 Ph.D. scientists and research associates.
At Human Genome Sciences, Inc., a prominent genomics company, Dr. Yu helped to establish the high-throughput gene discovery program. He also led the technology development group and cancer group. He identified and characterized numerous genes for therapeutic protein and drug discovery.
Dr. Yu was a Post-Doctoral Fellow at the HarvardMedicalSchool. He holds a Ph.D. degree in Molecular Biology from the University of California, Berkeley and a B.S. degree in Biochemistry from FudanUniversity, Shanghai, China. Dr. Yu also founded the Chinese Biopharmaceutical Association headquartered in WashingtonDC. He is coinventor and coauthor of more than 100 patents and scientific articles.
Bio for Dr. Wei Zhou
Dr. Zhou is the founder and CEO of Centrillion Biosciences, a leading genomic technology and service company in the Silicon Valley. He is also a senior advisor to Covington and Burling LLP, a top international law firm well known for its life sciences, regulatory and government relationship practices. Prior to founding Centrillion, he was a partner at the technology law firm Wilson Sonsini Goodrich & Rosati, where he advised technology start-ups. At Affymetrix (NASDAQ: AFFX) which pioneered the entire high throughput DNA analysis industry, he served as a senior vice president of intellectual property and advanced technology, responsible for intellectual property and technology management. He was also the founding China country manager and credited for building Affymetrix’ rapid growing China business and for establishing a number of translational medicine and biochip service centers in collaboration with the Chinese government. He was instrumental in establishing the first US-China joint technology biochip R&D program, which resulted in the commercialization of world’s first personal genechip system.
Additionally, Dr. Zhou was a partner at Jedi Venture partners and served as a director and advisory to start-up companies in digital media and life sciences industry. He is currently serving as the president and board member of Hua Yuan Science and Technology association (HYSTA), which focuses on promoting technology entrepreneurship in the US and China.
Dr. Zhou received his Ph.D. form Virginia Tech, his postdoctoral training from EmoryUniversityMedicalSchool and his J.D. from StanfordUniversityLawSchool. He also graduated from the Harvard Business School General Manager program.
Bio for Dr. Sofia Qiao
Sofie is a member of Russell Reynolds Associates’ Healthcare sector. Currently based in San Francisco with plans to relocate to China, she focuses on senior-level executive searches in the life sciences.
Prior to joining Russell Reynolds, she was a successful biotech entrepreneur and executive. She co-founded LEAD Therapeutics, a U.S.-China small molecule drug discovery company in 2006, raised $17 million in venture financing, and set up operations in both the U.S. and China. LEAD was acquired by BioMarin in 2010 for $97 million. Since LEAD’s exit, she has engaged in various startup entrepreneurial activities and advised several biotech companies. Prior to founding LEAD, she served in a variety of roles including general management, business development, strategy consulting and research at Discovery Partners International (a preclinical CRO), Syrrx (now Takeda California), McKinsey and Co., and Genzyme (now Sanofi). A native of Beijing, Sofie started her undergraduate studies at PekingUniversity and transferred to Harvard after two years where she received her A.B., magna cum laude, in chemistry. She received her Ph.D. in organic chemistry from MIT.
Bio for Dr. Heng Wei Chang
Principal and co-founder of CS Bio Co. Dr. Chang is an expert in peptide synthesis and cGMP production. He has synthesized over 10,000 peptides and designed and commercialized a series of fully automated peptide synthesizers. Dr. Chang was a principle scientist at Peninsula Laboratories prior to cofounding C S Bio in 1993. Starting out as strictly an automated peptide synthesis equipment manufacturer, C S Bio has grown into one of the leading research and cGMP peptide manufacturing companies worldwide. With 25+ years of industrial peptide experience, Dr. Chang is considered an expert in the field of solid phase peptide synthesis and peptide purification.
Bio for Dr. Jimmy Z. Zhang
Dr. Jimmy Zhang is Greater China Lead, Licensing, Acquisitions & External Research at Merck & Co., and a member of Leadership Team of MSD China R&D. He’s responsible for Merck’s licensing, acquisitions, research collaboration, alliance/partnership management and venture capital investments in Greater China.
Before joining Merck, Jimmy was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Synergenics invests and manages early-stage companies in drug discovery, vaccine, diagnostics, and healthcare IT. Jimmy is responsible for the business development and operations of Synergenics and some of its portfolio companies, and their businesses in China. He was also the executive vice president of ReLIA Diagnostic Systems and its wholly-owned China subsidiary ReLIA Biotechnologies (Shenzhen).
Jimmy was previously a consultant at McKinsey & Company traveling and working in China, US and Germany, a registered patent agent in the Palo Alto office of Morrison &Foerster, and a project manager at Chiron Corporation (now part of Novartis).
Jimmy received his B.S. in biochemistry from NanjingUniversity, and Ph.D. in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with two Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition.